SynCore Biotechnology Co (ROCO:4192) Cyclically Adjusted Revenue per Share: NT$0.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4192 SynCore Biotechnology Co Ltd ROCO:4192
69 GF Score
Price NT$19.95
GF Value NT$40.43
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is SynCore Biotechnology Co Cyclically Adjusted Revenue per Share?

SynCore Biotechnology Co ROCO:4192 -0.25% 69 Cyclically Adjusted Revenue per Share is NT$0.61 as of Jun. 2026. GuruFocus rates ROCO:4192 with a GF Score™ of 69/100 and a GF Value™ of NT$40.43 (Significantly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SynCore Biotechnology Co's adjusted revenue per share for the three months ended in Jun. 2026 was NT$0.177. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$0.61 for the trailing ten years ended in Jun. 2026.

During the past 12 months, SynCore Biotechnology Co's average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of SynCore Biotechnology Co was 1.80% per year. The lowest was 1.80% per year. And the median was 1.80% per year.

As of today (2026-08-26), SynCore Biotechnology Co's current stock price is NT$19.95. SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was NT$0.61. SynCore Biotechnology Co's Cyclically Adjusted PS Ratio of today is 32.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SynCore Biotechnology Co was 193.95. The lowest was 30.74. And the median was 61.95.


SynCore Biotechnology Co  (ROCO:4192) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SynCore Biotechnology Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.95/0.61
=32.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SynCore Biotechnology Co was 193.95. The lowest was 30.74. And the median was 61.95.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Related Terms


SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Chart

SynCore Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.55 0.59 0.62 0.58

SynCore Biotechnology Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.58 0.58 0.60 0.61

ROCO:4192 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, SynCore Biotechnology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynCore Biotechnology Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SynCore Biotechnology Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4192
69GF Score
SynCore Biotechnology Co Ltd ROCO:4192
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SynCore Biotechnology Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.177/333.9520*333.9520
=0.177

Current CPI (Jun. 2026) = 333.9520.

SynCore Biotechnology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.100 241.428 0.138
201612 0.106 241.432 0.147
201703 0.097 243.801 0.133
201706 0.120 244.955 0.164
201709 0.108 246.819 0.146
201712 0.105 246.524 0.142
201803 0.096 249.554 0.128
201806 0.103 251.989 0.137
201809 0.093 252.439 0.123
201812 0.085 251.233 0.113
201903 0.286 254.202 0.376
201906 0.103 256.143 0.134
201909 0.083 256.759 0.108
201912 0.080 256.974 0.104
202003 0.079 258.115 0.102
202006 0.060 257.797 0.078
202009 0.136 260.280 0.174
202012 0.196 260.474 0.251
202103 0.044 264.877 0.055
202106 0.041 271.696 0.050
202109 0.047 274.310 0.057
202112 0.092 278.802 0.110
202203 0.108 287.504 0.125
202206 0.093 296.311 0.105
202209 0.144 296.808 0.162
202212 0.163 296.797 0.183
202303 0.120 301.836 0.133
202306 0.147 305.109 0.161
202309 0.188 307.789 0.204
202312 0.172 306.746 0.187
202403 0.124 312.332 0.133
202406 0.199 314.175 0.212
202409 0.151 315.301 0.160
202412 0.187 315.605 0.198
202503 0.153 319.799 0.160
202506 0.222 322.561 0.230
202509 0.185 324.800 0.190
202512 0.210 324.054 0.216
202603 0.174 330.213 0.176
202606 0.177 333.952 0.177

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$0.61 mean?
SynCore Biotechnology Co (ROCO:4192) has a Cyclically Adjusted Revenue per Share of NT$0.61 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SynCore Biotechnology Co and its competitors.
Is SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share too high?
SynCore Biotechnology Co's current Cyclically Adjusted Revenue per Share is NT$0.61. Overall, SynCore Biotechnology Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share of NT$0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SynCore Biotechnology Co and its competitors. SynCore Biotechnology Co's current Cyclically Adjusted Revenue per Share is NT$0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynCore Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, SynCore Biotechnology Co (ROCO:4192) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$40.43, compared to a current price of NT$19.95 — trading 50.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$0.61. SynCore Biotechnology Co's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For SynCore Biotechnology Co (ROCO:4192), the current Cyclically Adjusted Revenue per Share is NT$0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?

Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued. The current stock price of NT$19.95 is trading 50.7% below its estimated GF Value™ of NT$40.43. GuruFocus considers SynCore Biotechnology Co to be Significantly Undervalued.

Key valuation signals for ROCO:4192:

  • Cyclically Adjusted Revenue per Share: NT$0.61
  • GF Value™: NT$40.43 vs. price of NT$19.95 (50.7% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SynCore Biotechnology Co Business Description

Address No. 84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
69GF Score

Get the complete analysis for ROCO:4192

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.95
Price
NT$40.43
GF Value